AnemiaNCT02222805
Effect of Timing of Umbilical Cord Clamping on Anaemia at 8 and 12 Months and Later Neurodevelopment
A study testing Early (≤30 seconds) cord clamping and Delayed (≤180 seconds) cord clamping in people with Anemia and Iron Deficiency, run by Uppsala University at 1 site in Nepal.
Trial summary
The investigators plan a study to randomize 540 children in Nepal to early (≤30 seconds) or late (≥180 seconds) clamping of the umbilical cord at birth. The children will be followed with blood tests (hemoglobin and ferritin) at 8 and 12 months of age, and their development is evaluated by questionnaire (Ages \&… Read more about this study
- Who is it for?
- Ages 34 to 41 weeksHealthy volunteers can take part
- Conditions the study is for
- Anemia, Iron Deficiency, Neonatal Jaundice
- What is being tested?
- Early (≤30 seconds) cord clamping and Delayed (≤180 seconds) cord clamping
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 540 participants
- Where
- 1 siteNepal
- Study dates
- Oct 2014to 11 Dec 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 34 to 41 weeks
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Late preterm or term pregnancy (gestational age 34 to 41 weeks)
- Vaginal delivery
Who cannot join
- Serious congenital malformation, syndrome or other congenital disease that can affect the outcome measures
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Timing of Umbilical Cord Clamping on Anaemia at 8 and 12 Months and Later Neurodevelopment in Late Pre-term and Term Infants; a Facility-based Randomized-controlled Trial in Nepal
The investigators plan a study to randomize 540 children in Nepal to early (≤30 seconds) or late (≥180 seconds) clamping of the umbilical cord at birth. The children will be followed with blood tests (hemoglobin and ferritin) at 8 and 12 months of age, and their development is evaluated by questionnaire (Ages \& Stages Questionnaire ) at 12 months of age, and by testing (Bayley -III) at 18-24 months of age. By implementing the project in a country with a high proportion of anemia at one year of age (about 75%), we can reduce the number of children in the study and still achieve significant results.
Iron deficiency is a global health problem and causes anemia and impaired neurodevelopment in children. Anemia is estimated by WHO to occur among 25% of all children before school age, and the corresponding figure in Europe is 3-9 %.
Read more
By waiting 3 minutes to clamp the cord after birth, a large part of the child's blood volume remaining in the placenta is transfused over to the child's body. Research shows that the neonate's blood volume can increase by about 40% and this blood contains 3 to 4 months' supply of iron. In Sweden, we have shown that late clamping of the umbilical cord could reduce iron deficiency in children at four months of age by 90%. Globally, most countries practice early cord clamping and the child is deprived of the placental blood transfusion. The hypothesis of the study is that by delaying the clamping of the umbilical cord, anemia at 8 and 12 months will be reduced an this in turn will be beneficial for the childrens development.
The project will be implemented at Paropakar Maternity and Women 's Hospital, Kathmandu. It hosts approximately 23,000 births annually.
Read the detailed description
Study Protocol Effect of timing of umbilical cord clamping on anaemia at 8 and 12 months and later neurodevelopment in late pre-term and term infants; a facility-based randomized-controlled trial in Nepal
Introduction At the time of birth, the infant is still attached to the placenta via the umbilical cord. The infant is usually separated from the placenta by clamping the cord with two clamps. This task takes place during the third stage of labour, which is the period of time from the birth of the infant to the delivery of the placenta.
Active management of the third stage of labour has been described in a recent World Health Organization (WHO) report as the "cornerstone" of obstetric and midwifery practice during the latter part of the 20th century. Active management has involved the clinician intervening in the process through three interrelated processes: the administration of an uterotonic drug; early cord clamping and cutting; and controlled traction of the umbilical cord.
Early cord clamping has been generally advised to be carried out in the first 30 seconds after birth, regardless of whether the cord pulsation has ceased. Due to evidence shown the last decade, recent guidelines for management of the third stage of labour no longer recommend immediate cord clamping but changes in practice is questioned and policies on hospitals are rare.
Possible beneficial and adverse effects:
Delayed clamping allows time for a transfer of the fetal blood in the placenta to the infant at the time of birth. This placental transfusion can provide the infant with an additional 40% more blood volume. The amount of blood returned to the infant depends on when the cord is clamped and at what level the infant is held prior to clamping. Neonatal benefits associated with this increased placental transfusion include higher haemoglobin concentrations, additional iron stores and less anaemia later in infancy, higher red blood cell flow to vital organs and better cardiopulmonary adaptation.
Delayed cord clamping has been linked to an increase in the incidence of jaundice which, in severe cases, could have longer term effects on the health and development of the infant.
Previous studies performed by the principal investigator in a high-income country has shown that delayed cord clamping, compared with early clamping, resulted in reduced prevalence of neonatal anaemia. Furthermore delayed, cord clamping improved iron status and reduced prevalence of iron deficiency (ID) at 4 months of age without demonstrable adverse effects. As ID in infants even without anaemia has been associated with impaired development , delayed cord clamping seems to benefit full term infants even in regions with a relatively low prevalence of ID anaemia.
Later effects on anaemia and development:
The improved iron stores at four to six months after delayed cord clamping suggests that ID anaemia could be reduced at eight to twelve months of age, but this could not be shown in the principal investigators latest study, possibly due to small sample size. Although ID anaemia is rare (3-9 %) in high income countries, the negative impact on children's health and development should not be underestimated. As an example, a 15 % reduction of anaemia in Sweden among toddlers (from 3 to 2,5 %) would help 500 children annually. No randomized trial has evaluated the effect of delayed versus early cord clamping on infants after 6 months of age in a low income country with high prevalence of iron deficiency and anaemia. As anaemia is associated with extensive health effects, such as stunting, fatigue and impaired neurodevelopment reducing anaemia in infants is an urgent need in a global perspective. In a recently published observational study from Peru, anaemia at eight months of age was evaluated at infants born before and after a hospital change of regime from early to delayed cord clamping. The study resulted in a significant reduction of anaemia by 16% (from 75 to 59%) as well as a significant higher level of haemoglobin.
Rationale for Study in Nepal:
In Nepal, children age 6-17 months have high anaemia prevalence (72-78%). Approximately 50% of all anaemia among preschoolers can be contributed to ID. By performing the planned study in a country with high anaemia prevalence, we can reduce sample size dramatically and still be able to detect significant effects on haemoglobin levels and neurodevelopment.
Study Objective:
To evaluate the effects of delayed and early cord clamping on
- Anaemia (and haemoglobin level) at 8 and 12 months
- Ferritin at 8 and 12 months
- Bilirubin at 2-3 days
- Admission to the neonatal intensive care unit (NICU) or special care nursery
- Development at 12 and 18-24 months of age.
Primary outcome:
The primary outcome will be infant haemoglobin 8 and 12 months of age.
Secondary outcomes:
The secondary outcome will be neonatal morbidity (need for phototherapy, and respiratory symptoms). Maternal postpartum haemorrhage; effects of delayed and early cord clamping on iron status at 8 and 12 months of age; psychomotor development at 12 months of age assessed by the Ages and Stages Questionnaire and development evaluated by The Bayley Scales of Infant and Toddler Development at 18-24 months.
Methods
Trial design and Participants:
Randomized controlled trial comparing delayed and early cord clamping will be implemented in the hospital. The study will be conducted at the Paropakar Maternity and Women's Hospital, Nepal.
Pregnant women are eligible if they meet the following criteria:
- Late preterm or term pregnancy (gestational age 34 to 41 weeks)
- Single pregnancy with expected vaginal delivery
- Mother/family give consent to return for follow-up at 8 and 12 months
Exclusion criteria are serious congenital malformations, syndromes, or other congenital diseases that could affect the outcome measures.
Intervention:
When delivery is imminent (expected within 10 minutes), the midwife will opened a sealed, numbered, opaque envelope containing the treatment allocation. The interventions consist of delayed clamping of the umbilical cord (≥180 seconds after delivery) or early clamping of the umbilical cord (≤60 s). The time from complete delivery of the baby to the first clamp on the umbilical cord will be measured with a stopwatch by the midwife's assistant or the surveillance officer. All other aspects of obstetric care will be managed according to standard practice at the hospital. In both groups, oxytocin will be given to the mother after the umbilical cord is clamped. All staff in the delivery unit will be trained in the study procedures before the trial started.
Follow-up:
After the delivery, the babies will be cared for according to clinical routines, and early breast feeding will be encouraged. As part of the study, the infant will be assessed at 1 and 6 hours by the midwife, who will record if the baby has been breast fed and the presence of respiratory symptoms (that is, respiratory rate >60 breaths/minute, presence of nostril flaring, grunting, or intercostal retractions).
Infants will stay at the postnatal ward with their mothers for two or three days, except for well babies whose mothers preferred to leave the hospital earlier and infants who requires admission to the neonatal unit. Transcutaneous bilirubin will be checked at 24 and 48 hours of age if newborn is still at the hospital, and before discharge.
At 8 and 12 months of age, infants will be scheduled for a follow-up visit including blood sampling (hemoglobin and ferritin) and weight and length measurements. Venous blood sampling will be performed. Before the visit, parents will be asked to complete a three day food diary to assess whether the infant was exclusively or partially breast fed and whether formula or solids were given. Parent will be assisted in answering the Ages \& Stages Questionnaire.
If funding is achieved, children wil be examined by The Bayley Scales of Infant and Toddler Development, Third Edition at 18-24 months of age.
Physicians performing neonatal examinations, staff members responsible for collection of blood samples and background data, and laboratory staff performing analyses of blood samples will be blinded to each infant's allocation group.
Additional data collection:
The following information will be collected from maternal healthcare records: reported illness, medication, parity, weight, height, smoking habits at the time of admission.
Sample size:
The sample size for the primary outcome at eight months was estimated to find a difference of 15% (70% versus 55%) in the prevalence of anaemia between the two randomization groups with a power of 80% and a type I error rate of .05. Using Fisher's exact-test to analyze outcome data a group size of 176 would be needed. Taking into account an attrition rate of 35% we calculate to include 270 newborns in each group, i.e. a total of 540.
Ethical considerations:
All research involving newborn infants and small children need careful ethical considerations, mainly since the subjects themselves can't agree to whether they want to participate in the study or not. In particular, research that is not immediately of benefit for the patients needs ethical consideration. The included infants are healthy full-term infants undergoing umbilical cord clamping, which is a standard procedure after birth. The possible benefit of the intervention (delayed cord clamping) of increasing iron stores and preventing infant anaemia is estimated to be higher than the risk of probable adverse effects, such as hyperbilirubinaemia. Ethical approval has be sought and obtained from Nepal Health Research Council (June 6, 2014, 76/2014). Written informed parental consent will be obtained before the intervention, and parents can withdraw from the study at any time without any need for explanations.
Discussion and Policy Implication:
Reducing ID among infants is important as it is associated with impaired neurodevelopment. In Sweden, ID has been found among 26% of 12 months old infants. With high global prevalence of infant anaemia, delayed cord clamping has the potential to reduce infant anaemia and thereby improve infants' and children's health and development. In crude numbers, a reduction by 10% would mean an annual reduction of 60 000 infants with anaemia in Nepal. The trial is important to perform as although strong indications exists on the effect of delayed cord clamping on anaemia at 8 to 12 months of age, it has not been evaluated by a randomized trial. By the proposed study, outcome as well as safety effects will be analyzed, and results might not only contribute to the practice in Nepal, but also to the global community, in particular low income countries with a high prevalence of ID anaemia.
- Conditions
- Anemia, Iron Deficiency, Neonatal Jaundice
- Being tested
- Early (≤30 seconds) cord clamping, Delayed (≤180 seconds) cord clamping
- Keywords
- Cord clamping, Iron deficiency, Anemia, Iron, Hyperbilirubinemia, Jaundice, Neurodevelopment
- Medical subject headings
- Anemia, Iron Deficiencies, Jaundice, Neonatal, Hyperbilirubinemia, Jaundice
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Early (≤30 seconds) cord clampingProcedure or surgery
Also called Immediate cord clamping
Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
Delayed (≤180 seconds) cord clampingProcedure or surgery
Also called Late cord clamping, Deferred cord clamping, Optimal cord clamping
Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
| Study group | Role | What they receive |
|---|---|---|
| Early cord clamping (ECC) | Other | Early (≤30 seconds) cord clamping of the umbilical cord after delivery. Receives: Procedure: Early (≤30 seconds) cord clamping |
| Delayed cord clamping (DCC) | Other | Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery. Receives: Procedure: Delayed (≤180 seconds) cord clamping |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hemoglobin
Hemoglobin will be analyzed be comparing means and as a categorical variable, defining anemia as Hemoglobin < 110 g/L
Measured: 8 months plus/minus one month
Secondary outcomes (8)
Hemoglobin
Hemoglobin will be analyzed be comparing means and as a categorical variable, defining anemia as Hemoglobin < 110 g/L
Measured: 12 months plus/minus one month
Ferritin
Ferritin will be analyzed be comparing means and as a categorical variable, defining iron deficiency as Ferritin < 12 μg/L
Measured: 8 months plus/minus one month
Ferritin
Ferritin will be analyzed be comparing means and as a categorical variable, defining iron deficiency as Ferritin < 12 μg/L
Measured: 12 months plus/minus one month
Iron deficiency anemia
Defining iron deficiency as a combination of Hemoglobin < 110 g/L and Ferritin < 12 μg/L
Measured: 8 months plus/minus one month
Iron deficiency anemia
Defining iron deficiency as a combination of Hemoglobin < 110 g/L and Ferritin < 12 μg/L
Measured: 12 months plus/minus one month
Bilirubin
Measured by a transcutaneous method.
Measured: 2 days
Psychomotor development assessed by the Ages and Stages Questionnaire.
Ages and Stages Questionnaire is a parent report questionnaire available for developmental screening of children from one month to 5 ½ years. 30 questions are divided into 5 developmental domains (communication, gross motor, fine motor, problem solving and personal-social). Total score and scores within separate domains from the 48-month questionnaire will be assessed.
Measured: 12 months
Psychomotor development assessed by Bayley Scales of Infant and Toddler Development 3rd ed. (Bayley III)
Measured: 18 months plus 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2014 (estimated)
- Study startOct 2014
- Primary completionDec 2014
- Study completion11 Dec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for AnemiaStudies of the same condition, open and under way.
- More trials run by Uppsala UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 540 participants (actual)
Sponsor and investigators
- Lead sponsor
- Uppsala University
- Sponsor type
- University, hospital or other
- Collaborators
- UNICEF, Ministry of Health and Population, Nepal, The Swedish Society of Medicine
- Responsible party
- Sponsor
- Investigators
- Ola Andersson, MD PhD, Principal investigator, Uppsala UniversityAshish KC, MD, Principal investigator, Uppsala University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02222805
- Sponsor's protocol ID
- CCANEMIA11
- Status last verified
- Jun 2023
- First submitted
- 19 Aug 2014
- Last updated
- 22 Jun 2023
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Andersson O, Hellstrom-Westas L, Andersson D, Domellof M. Effect of delayed versus early umbilical cord clamping on neonatal outcomes and iron status at 4 months: a randomised controlled trial. BMJ. 2011 Nov 15;343:d7157. doi: 10.1136/bmj.d7157.
PubMed 22089242Andersson O, Domellof M, Andersson D, Hellstrom-Westas L. Effect of delayed vs early umbilical cord clamping on iron status and neurodevelopment at age 12 months: a randomized clinical trial. JAMA Pediatr. 2014 Jun;168(6):547-54. doi: 10.1001/jamapediatrics.2013.4639.
PubMed 24756128Kc A, Rana N, Malqvist M, Jarawka Ranneberg L, Subedi K, Andersson O. Effects of Delayed Umbilical Cord Clamping vs Early Clamping on Anemia in Infants at 8 and 12 Months: A Randomized Clinical Trial. JAMA Pediatr. 2017 Mar 1;171(3):264-270. doi: 10.1001/jamapediatrics.2016.3971.
PubMed 28114607Rana N, Kc A, Malqvist M, Subedi K, Andersson O. Effect of Delayed Cord Clamping of Term Babies on Neurodevelopment at 12 Months: A Randomized Controlled Trial. Neonatology. 2019;115(1):36-42. doi: 10.1159/000491994. Epub 2018 Oct 2.
PubMed 30278462Rana N, Ranneberg LJ, Malqvist M, Kc A, Andersson O. Delayed cord clamping was not associated with an increased risk of hyperbilirubinaemia on the day of birth or jaundice in the first 4 weeks. Acta Paediatr. 2020 Jan;109(1):71-77. doi: 10.1111/apa.14913. Epub 2019 Jul 15.
PubMed 31240753Berg JHM, Isacson M, Basnet O, Gurung R, Subedi K, Kc A, Andersson O. Effect of Delayed Cord Clamping on Neurodevelopment at 3 Years: A Randomized Controlled Trial. Neonatology. 2021;118(3):282-288. doi: 10.1159/000515838. Epub 2021 May 7.
PubMed 33965945Kc A, Malqvist M, Rana N, Ranneberg LJ, Andersson O. Effect of timing of umbilical cord clamping on anaemia at 8 and 12 months and later neurodevelopment in late pre-term and term infants; a facility-based, randomized-controlled trial in Nepal. BMC Pediatr. 2016 Mar 10;16:35. doi: 10.1186/s12887-016-0576-z.
PubMed 26965317
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Timing of Umbilical Cord Clamping on Anaemia at 8 and 12 Months and Later Neurodevelopment in Late Pre-term and Term Infants; a Facility-based Randomized-controlled Trial in Nepal
- ClinicalTrials.gov ID
- NCT02222805
- Acronym / sponsor ID
- CCANEMIA11
- Conditions
- Anemia, Iron Deficiency, Neonatal Jaundice
- Keywords
- Cord clamping, Iron deficiency, Anemia, Iron, Hyperbilirubinemia, Jaundice, Neurodevelopment
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 540 participants (actual)
- Lead sponsor
- Uppsala UniversityUniversity, hospital or other
- Collaborators
- UNICEF, Ministry of Health and Population, Nepal, The Swedish Society of Medicine
- Study start
- Oct 2014 (actual)
- Primary completion
- Dec 2014 (actual)
- Study completion
- 11 Dec 2015 (actual)
- First posted
- 21 Aug 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators plan a study to randomize 540 children in Nepal to early (≤30 seconds) or late (≥180 seconds) clamping of the umbilical cord at birth. The children will be followed with blood tests (hemoglobin and ferritin) at 8 and 12 months of age, and their development is evaluated by questionnaire (Ages \& Stages Questionnaire ) at 12 months of age, and by testing (Bayley -III) at 18-24 months of age. By implementing the project in a country with a high proportion of anemia at one year of age (about 75%), we can reduce the number of children in the study and still achieve significant results.
Iron deficiency is a global health problem and causes anemia and impaired neurodevelopment in children. Anemia is estimated by WHO to occur among 25% of all children before school age, and the corresponding figure in Europe is 3-9 %.
By waiting 3 minutes to clamp the cord after birth, a large part of the child's blood volume remaining in the placenta is transfused over to the child's body. Research shows that the neonate's blood volume can increase by about 40% and this blood contains 3 to 4 months' supply of iron. In Sweden, we have shown that late clamping of the umbilical cord could reduce iron deficiency in children at four months of age by 90%. Globally, most countries practice early cord clamping and the child is deprived of the placental blood transfusion. The hypothesis of the study is that by delaying the clamping of the umbilical cord, anemia at 8 and 12 months will be reduced an this in turn will be beneficial for the childrens development.
The project will be implemented at Paropakar Maternity and Women 's Hospital, Kathmandu. It hosts approximately 23,000 births annually.
Detailed description
Study Protocol Effect of timing of umbilical cord clamping on anaemia at 8 and 12 months and later neurodevelopment in late pre-term and term infants; a facility-based randomized-controlled trial in Nepal
Introduction At the time of birth, the infant is still attached to the placenta via the umbilical cord. The infant is usually separated from the placenta by clamping the cord with two clamps. This task takes place during the third stage of labour, which is the period of time from the birth of the infant to the delivery of the placenta.
Active management of the third stage of labour has been described in a recent World Health Organization (WHO) report as the "cornerstone" of obstetric and midwifery practice during the latter part of the 20th century. Active management has involved the clinician intervening in the process through three interrelated processes: the administration of an uterotonic drug; early cord clamping and cutting; and controlled traction of the umbilical cord.
Early cord clamping has been generally advised to be carried out in the first 30 seconds after birth, regardless of whether the cord pulsation has ceased. Due to evidence shown the last decade, recent guidelines for management of the third stage of labour no longer recommend immediate cord clamping but changes in practice is questioned and policies on hospitals are rare.
Possible beneficial and adverse effects:
Delayed clamping allows time for a transfer of the fetal blood in the placenta to the infant at the time of birth. This placental transfusion can provide the infant with an additional 40% more blood volume. The amount of blood returned to the infant depends on when the cord is clamped and at what level the infant is held prior to clamping. Neonatal benefits associated with this increased placental transfusion include higher haemoglobin concentrations, additional iron stores and less anaemia later in infancy, higher red blood cell flow to vital organs and better cardiopulmonary adaptation.
Delayed cord clamping has been linked to an increase in the incidence of jaundice which, in severe cases, could have longer term effects on the health and development of the infant.
Previous studies performed by the principal investigator in a high-income country has shown that delayed cord clamping, compared with early clamping, resulted in reduced prevalence of neonatal anaemia. Furthermore delayed, cord clamping improved iron status and reduced prevalence of iron deficiency (ID) at 4 months of age without demonstrable adverse effects. As ID in infants even without anaemia has been associated with impaired development , delayed cord clamping seems to benefit full term infants even in regions with a relatively low prevalence of ID anaemia.
Later effects on anaemia and development:
The improved iron stores at four to six months after delayed cord clamping suggests that ID anaemia could be reduced at eight to twelve months of age, but this could not be shown in the principal investigators latest study, possibly due to small sample size. Although ID anaemia is rare (3-9 %) in high income countries, the negative impact on children's health and development should not be underestimated. As an example, a 15 % reduction of anaemia in Sweden among toddlers (from 3 to 2,5 %) would help 500 children annually. No randomized trial has evaluated the effect of delayed versus early cord clamping on infants after 6 months of age in a low income country with high prevalence of iron deficiency and anaemia. As anaemia is associated with extensive health effects, such as stunting, fatigue and impaired neurodevelopment reducing anaemia in infants is an urgent need in a global perspective. In a recently published observational study from Peru, anaemia at eight months of age was evaluated at infants born before and after a hospital change of regime from early to delayed cord clamping. The study resulted in a significant reduction of anaemia by 16% (from 75 to 59%) as well as a significant higher level of haemoglobin.
Rationale for Study in Nepal:
In Nepal, children age 6-17 months have high anaemia prevalence (72-78%). Approximately 50% of all anaemia among preschoolers can be contributed to ID. By performing the planned study in a country with high anaemia prevalence, we can reduce sample size dramatically and still be able to detect significant effects on haemoglobin levels and neurodevelopment.
Study Objective:
To evaluate the effects of delayed and early cord clamping on
- Anaemia (and haemoglobin level) at 8 and 12 months
- Ferritin at 8 and 12 months
- Bilirubin at 2-3 days
- Admission to the neonatal intensive care unit (NICU) or special care nursery
- Development at 12 and 18-24 months of age.
Primary outcome:
The primary outcome will be infant haemoglobin 8 and 12 months of age.
Secondary outcomes:
The secondary outcome will be neonatal morbidity (need for phototherapy, and respiratory symptoms). Maternal postpartum haemorrhage; effects of delayed and early cord clamping on iron status at 8 and 12 months of age; psychomotor development at 12 months of age assessed by the Ages and Stages Questionnaire and development evaluated by The Bayley Scales of Infant and Toddler Development at 18-24 months.
Methods
Trial design and Participants:
Randomized controlled trial comparing delayed and early cord clamping will be implemented in the hospital. The study will be conducted at the Paropakar Maternity and Women's Hospital, Nepal.
Pregnant women are eligible if they meet the following criteria:
- Late preterm or term pregnancy (gestational age 34 to 41 weeks)
- Single pregnancy with expected vaginal delivery
- Mother/family give consent to return for follow-up at 8 and 12 months
Exclusion criteria are serious congenital malformations, syndromes, or other congenital diseases that could affect the outcome measures.
Intervention:
When delivery is imminent (expected within 10 minutes), the midwife will opened a sealed, numbered, opaque envelope containing the treatment allocation. The interventions consist of delayed clamping of the umbilical cord (≥180 seconds after delivery) or early clamping of the umbilical cord (≤60 s). The time from complete delivery of the baby to the first clamp on the umbilical cord will be measured with a stopwatch by the midwife's assistant or the surveillance officer. All other aspects of obstetric care will be managed according to standard practice at the hospital. In both groups, oxytocin will be given to the mother after the umbilical cord is clamped. All staff in the delivery unit will be trained in the study procedures before the trial started.
Follow-up:
After the delivery, the babies will be cared for according to clinical routines, and early breast feeding will be encouraged. As part of the study, the infant will be assessed at 1 and 6 hours by the midwife, who will record if the baby has been breast fed and the presence of respiratory symptoms (that is, respiratory rate >60 breaths/minute, presence of nostril flaring, grunting, or intercostal retractions).
Infants will stay at the postnatal ward with their mothers for two or three days, except for well babies whose mothers preferred to leave the hospital earlier and infants who requires admission to the neonatal unit. Transcutaneous bilirubin will be checked at 24 and 48 hours of age if newborn is still at the hospital, and before discharge.
At 8 and 12 months of age, infants will be scheduled for a follow-up visit including blood sampling (hemoglobin and ferritin) and weight and length measurements. Venous blood sampling will be performed. Before the visit, parents will be asked to complete a three day food diary to assess whether the infant was exclusively or partially breast fed and whether formula or solids were given. Parent will be assisted in answering the Ages \& Stages Questionnaire.
If funding is achieved, children wil be examined by The Bayley Scales of Infant and Toddler Development, Third Edition at 18-24 months of age.
Physicians performing neonatal examinations, staff members responsible for collection of blood samples and background data, and laboratory staff performing analyses of blood samples will be blinded to each infant's allocation group.
Additional data collection:
The following information will be collected from maternal healthcare records: reported illness, medication, parity, weight, height, smoking habits at the time of admission.
Sample size:
The sample size for the primary outcome at eight months was estimated to find a difference of 15% (70% versus 55%) in the prevalence of anaemia between the two randomization groups with a power of 80% and a type I error rate of .05. Using Fisher's exact-test to analyze outcome data a group size of 176 would be needed. Taking into account an attrition rate of 35% we calculate to include 270 newborns in each group, i.e. a total of 540.
Ethical considerations:
All research involving newborn infants and small children need careful ethical considerations, mainly since the subjects themselves can't agree to whether they want to participate in the study or not. In particular, research that is not immediately of benefit for the patients needs ethical consideration. The included infants are healthy full-term infants undergoing umbilical cord clamping, which is a standard procedure after birth. The possible benefit of the intervention (delayed cord clamping) of increasing iron stores and preventing infant anaemia is estimated to be higher than the risk of probable adverse effects, such as hyperbilirubinaemia. Ethical approval has be sought and obtained from Nepal Health Research Council (June 6, 2014, 76/2014). Written informed parental consent will be obtained before the intervention, and parents can withdraw from the study at any time without any need for explanations.
Discussion and Policy Implication:
Reducing ID among infants is important as it is associated with impaired neurodevelopment. In Sweden, ID has been found among 26% of 12 months old infants. With high global prevalence of infant anaemia, delayed cord clamping has the potential to reduce infant anaemia and thereby improve infants' and children's health and development. In crude numbers, a reduction by 10% would mean an annual reduction of 60 000 infants with anaemia in Nepal. The trial is important to perform as although strong indications exists on the effect of delayed cord clamping on anaemia at 8 to 12 months of age, it has not been evaluated by a randomized trial. By the proposed study, outcome as well as safety effects will be analyzed, and results might not only contribute to the practice in Nepal, but also to the global community, in particular low income countries with a high prevalence of ID anaemia.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Early cord clamping (ECC) | Other | Procedure: Early (≤30 seconds) cord clampingEarly (≤30 seconds) cord clamping of the umbilical cord after delivery. |
| Delayed cord clamping (DCC) | Other | Procedure: Delayed (≤180 seconds) cord clampingDelayed (≤180 seconds) cord clamping of the umbilical cord after delivery. |
Who may qualify
- Ages
- 34 to 41 weeks
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- Late preterm or term pregnancy (gestational age 34 to 41 weeks)
- Vaginal delivery
Key exclusion criteria (1 listed)
- Serious congenital malformation, syndrome or other congenital disease that can affect the outcome measures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Early (≤30 seconds) cord clampingAlso: Immediate cord clampingEarly (≤30 seconds) cord clamping of the umbilical cord after delivery. | Procedure or surgery | Early cord clamping (ECC) |
| Delayed (≤180 seconds) cord clampingAlso: Late cord clamping, Deferred cord clamping, Optimal cord clampingDelayed (≤180 seconds) cord clamping of the umbilical cord after delivery. | Procedure or surgery | Delayed cord clamping (DCC) |
Primary outcome
Hemoglobin
Time frame: 8 months plus/minus one month
Hemoglobin will be analyzed be comparing means and as a categorical variable, defining anemia as Hemoglobin < 110 g/L
8 secondary outcomes
Hemoglobin
Time frame: 12 months plus/minus one month
Ferritin
Time frame: 8 months plus/minus one month
Ferritin
Time frame: 12 months plus/minus one month
Iron deficiency anemia
Time frame: 8 months plus/minus one month
Iron deficiency anemia
Time frame: 12 months plus/minus one month
Bilirubin
Time frame: 2 days
Psychomotor development assessed by the Ages and Stages Questionnaire.
Time frame: 12 months
Psychomotor development assessed by Bayley Scales of Infant and Toddler Development 3rd ed. (Bayley III)
Time frame: 18 months plus 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2023.
- Background: PubMed 22089242Andersson O, Hellstrom-Westas L, Andersson D, Domellof M. Effect of delayed versus early umbilical cord clamping on neonatal outcomes and iron status at 4 months: a randomised controlled trial. BMJ. 2011 Nov 15;343:d7157. doi: 10.1136/bmj.d7157.
- Background: PubMed 24756128Andersson O, Domellof M, Andersson D, Hellstrom-Westas L. Effect of delayed vs early umbilical cord clamping on iron status and neurodevelopment at age 12 months: a randomized clinical trial. JAMA Pediatr. 2014 Jun;168(6):547-54. doi: 10.1001/jamapediatrics.2013.4639.
- Results publication: PubMed 28114607Kc A, Rana N, Malqvist M, Jarawka Ranneberg L, Subedi K, Andersson O. Effects of Delayed Umbilical Cord Clamping vs Early Clamping on Anemia in Infants at 8 and 12 Months: A Randomized Clinical Trial. JAMA Pediatr. 2017 Mar 1;171(3):264-270. doi: 10.1001/jamapediatrics.2016.3971.
- Results publication: PubMed 30278462Rana N, Kc A, Malqvist M, Subedi K, Andersson O. Effect of Delayed Cord Clamping of Term Babies on Neurodevelopment at 12 Months: A Randomized Controlled Trial. Neonatology. 2019;115(1):36-42. doi: 10.1159/000491994. Epub 2018 Oct 2.
- Results publication: PubMed 31240753Rana N, Ranneberg LJ, Malqvist M, Kc A, Andersson O. Delayed cord clamping was not associated with an increased risk of hyperbilirubinaemia on the day of birth or jaundice in the first 4 weeks. Acta Paediatr. 2020 Jan;109(1):71-77. doi: 10.1111/apa.14913. Epub 2019 Jul 15.
- Derived from this study: PubMed 33965945Berg JHM, Isacson M, Basnet O, Gurung R, Subedi K, Kc A, Andersson O. Effect of Delayed Cord Clamping on Neurodevelopment at 3 Years: A Randomized Controlled Trial. Neonatology. 2021;118(3):282-288. doi: 10.1159/000515838. Epub 2021 May 7.
- Derived from this study: PubMed 26965317Kc A, Malqvist M, Rana N, Ranneberg LJ, Andersson O. Effect of timing of umbilical cord clamping on anaemia at 8 and 12 months and later neurodevelopment in late pre-term and term infants; a facility-based, randomized-controlled trial in Nepal. BMC Pediatr. 2016 Mar 10;16:35. doi: 10.1186/s12887-016-0576-z.
- Individual participant dataSharing planned: No
Related trials for Anemia
RecruitingPhase 1/2
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
Aplastic Anemia, Refractory
Active, not recruitingPhase 1
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
RecruitingPhase 1/2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ola Andersson, MD PhD principal investigator
Uppsala University
Ashish KC, MD principal investigator
Uppsala University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Early (≤30 seconds) cord clamping and Delayed (≤180 seconds) cord clamping in people with Anemia and Iron Deficiency, run by Uppsala University at 1 site in Nepal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Nepal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hemoglobin (time frame: 8 months plus/minus one month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02222805, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2023.